Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tao Sun
Observed names:
T Sun,
T. Sun,
Tingting Sun
Institutions:
Liaoning Cancer Hospital & Institute,
China Medical University
Observed institutions:
Liaoning Cancer Hospital & Institute,
China Medical University
ORCID:
0000-0001-5931-386X
Observed ORCID:
0000-0001-5931-386X
OpenAlex ID:
A5135455849
Epstein–Barr virus reprograms immune escape in nasopharyngeal carcinoma
2026
·
Qifang Liu
, Yujing Tong
, et al.
·
Virulence
·
2
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
2026
·
Peng Yuan
, Yunjiang Liu
, et al.
·
JAMA Oncology
·
1
Final results of a phase II study of utidelone capsule, the first solid oral microtubule stabilizer, in metastatic breast cancer patients.
2026
·
Binghe Xu
, Tao Sun
, et al.
·
Journal of Clinical Oncology
·
1
Real-world Treatment Patterns Among Patients With Chemotherapy-induced Peripheral Neuropathy in China: The Retrospective, Observational ReTARdant Study (P8-14.008)
2026
·
Xiaoyu Zhai
, Peng Mao
, et al.
·
Neurology
Influence of precision treatment with artificial intelligence–assisted subtyping on first-line therapeutic efficacy in HR+/HER2– breast cancer.
2026
·
Wenjuan Zhang
, Tao Sun
, et al.
·
Journal of Clinical Oncology
Nimotuzumab combined with paclitaxel and cisplatin as first-line treatment for metastatic esophageal squamous cell carcinoma: A prospective, multicenter, double-blind, randomized controlled clinical study.
2026
·
Zhihao Lu
, Miaozhen Qiu
, et al.
·
Journal of Clinical Oncology
Efficacy and safety results of a prospective phase II study (IPUtrial) of inetetamab and pyrotinib in combination with utidelone for first- or second-line treatment of HER2-positive metastatic breast cancer.
2026
·
Hui Cao
, Tao Sun
, et al.
·
Journal of Clinical Oncology
Culmerciclib (CDK2/4/6 inhibitor) plus fulvestrant in HR+/HER2− advanced breast cancer after progression on CDK4/6i: Preliminary results from a phase II trial.
2026
·
Tao Sun
, Quchang Ouyang
, et al.
·
Journal of Clinical Oncology
Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy
2026
·
Yilin Li
, Huiyue Zhang
, et al.
·
Cancer Biology and Medicine
PDF
493P Evaluation of the safety and efficacy of HB0025 in combination with chemotherapy as first-line treatment for triple-negative breast cancer: Results of a phase II study
2026
·
Y. Meng
, J. Zhang
, et al.
·
ESMO Open
[Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial].
2026
·
Y F Jia
, J Xia
, et al.
·
PubMed
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study
2026
·
Lina Zhang
, Jingxuan Wang
, et al.
·
癌症:英文版
Show more works
View as search
Works count:
12
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type